BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

289 related articles for article (PubMed ID: 9636735)

  • 21. [Role of 18Fluorine-deoxyglucose (FDG) positron emission tomography in the management of lymphomas].
    Massardo V T; Canessa G J; Jofré M MJ; González E P; Humeres A P; Sierralta G P
    Rev Med Chil; 2006 Jul; 134(7):910-9. PubMed ID: 17130976
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Evaluation of treatment response in patients with lymphoma using [18F]FDG-PET: differences between non-Hodgkin's lymphoma and Hodgkin's disease.
    Spaepen K; Mortelmans L
    Q J Nucl Med; 2001 Sep; 45(3):269-73. PubMed ID: 11788819
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Positron emission tomography (PET) for staging low-grade non-Hodgkin's lymphomas (NHL).
    Najjar F; Hustinx R; Jerusalem G; Fillet G; Rigo P
    Cancer Biother Radiopharm; 2001 Aug; 16(4):297-304. PubMed ID: 11603000
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Comparison of findings with 18-FDG PET and CT in pretherapeutic staging of malignant lymphoma].
    Thill R; Neuerburg J; Fabry U; Cremerius U; Wagenknecht G; Hellwig D; Osieka R; Günther R; Büll U
    Nuklearmedizin; 1997 Oct; 36(7):234-9. PubMed ID: 9441282
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Whole-body positron emission tomography (PET) for diagnosis of residual mass in patients with lymphoma.
    de Wit M; Bumann D; Beyer W; Herbst K; Clausen M; Hossfeld DK
    Ann Oncol; 1997; 8 Suppl 1():57-60. PubMed ID: 9187431
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Imaging of malignant lymphomas with F-18 FDG coincidence detection positron emission tomography.
    Hwang K; Park CH; Kim HC; Kim H; Yoon S; Pai M; Kim S
    Clin Nucl Med; 2000 Oct; 25(10):789-95. PubMed ID: 11043718
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Correlation between glycolytic activity on [18F]-FDG-PET and cell density on diffusion-weighted MRI in lymphoma at staging.
    Giraudo C; Karanikas G; Weber M; Raderer M; Jaeger U; Simonitsch-Klupp I; Mayerhoefer ME
    J Magn Reson Imaging; 2018 May; 47(5):1217-1226. PubMed ID: 29086453
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The role of FDG-PET imaging in the management of lymphoma.
    Kostakoglu L; Leonard JP; Coleman M; Goldsmith SJ
    Clin Adv Hematol Oncol; 2004 Feb; 2(2):115-21. PubMed ID: 16163171
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Clinical value of FDG PET using coincident gamma cameras in staging and restaging of malignant lymphoma--compared with convenitonal diagnostic methods].
    Pichler R; Maschek W; Hatzl-Griesenhofer M; Huber H; Wimmer G; Wahl G; Fridrik M
    Nuklearmedizin; 2000 Sep; 39(6):166-73. PubMed ID: 11057408
    [TBL] [Abstract][Full Text] [Related]  

  • 30. FDG-PET in 10 children with non-Hodgkin's lymphoma: initial experience in staging and follow-up.
    Amthauer H; Furth C; Denecke T; Hundsdoerfer P; Voelker T; Seeger K; Stöver B; Henze G
    Klin Padiatr; 2005; 217(6):327-33. PubMed ID: 16307418
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The use of positron emission tomography with [18F] 2-fluoro-D-2-deoxyglucose (FDG-PET) in Hodgkin and non-Hodgkin's lymphoma.
    Chiusolo P; Sica S; Leone G
    Hematology; 2003 Dec; 8(6):403-8. PubMed ID: 14668036
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Positron emission tomography/computed tomography: diagnostic accuracy in lymphoma.
    Hernandez-Maraver D; Hernandez-Navarro F; Gomez-Leon N; Coya J; Rodriguez-Vigil B; Madero R; Pinilla I; Martin-Curto LM
    Br J Haematol; 2006 Nov; 135(3):293-302. PubMed ID: 17032175
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Whole-body FDG-PET imaging for staging of Hodgkin's disease and lymphoma.
    Hoh CK; Glaspy J; Rosen P; Dahlbom M; Lee SJ; Kunkel L; Hawkin RA; Maddahi J; Phelps ME
    J Nucl Med; 1997 Mar; 38(3):343-8. PubMed ID: 9074514
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Positron emission tomography in the detection and staging of ocular adnexal lymphoproliferative disease.
    Valenzuela AA; Allen C; Grimes D; Wong D; Sullivan TJ
    Ophthalmology; 2006 Dec; 113(12):2331-7. PubMed ID: 16996604
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Whole body positron emission tomography in the treatment of Hodgkin disease.
    Hueltenschmidt B; Sautter-Bihl ML; Lang O; Maul FD; Fischer J; Mergenthaler HG; Bihl H
    Cancer; 2001 Jan; 91(2):302-10. PubMed ID: 11180075
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Utility of fluorodeoxyglucose-PET imaging in the management of patients with Hodgkin's and non-Hodgkin's lymphomas.
    Kumar R; Maillard I; Schuster SJ; Alavi A
    Radiol Clin North Am; 2004 Nov; 42(6):1083-100. PubMed ID: 15488559
    [TBL] [Abstract][Full Text] [Related]  

  • 37. FDG-PET/CT in re-staging of patients with lymphoma.
    Freudenberg LS; Antoch G; Schütt P; Beyer T; Jentzen W; Müller SP; Görges R; Nowrousian MR; Bockisch A; Debatin JF
    Eur J Nucl Med Mol Imaging; 2004 Mar; 31(3):325-9. PubMed ID: 14647988
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The impact of FDG positron emission tomography imaging on the management of lymphomas.
    Shah N; Hoskin P; McMillan A; Gibson P; Lowe J; wong WL
    Br J Radiol; 2000 May; 73(869):482-7. PubMed ID: 10884743
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Role of fluorine-18 fluoro-deoxyglucose positron emission tomography scan in the evaluation and follow-up of patients with low-grade lymphomas.
    Karam M; Novak L; Cyriac J; Ali A; Nazeer T; Nugent F
    Cancer; 2006 Jul; 107(1):175-83. PubMed ID: 16721817
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The utility of FDG PET in diagnosis and follow-up of lymphoma in childhood.
    Sioka C
    Eur J Pediatr; 2013 Jun; 172(6):733-8. PubMed ID: 23559330
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.